Navigation Links
Tax Specialty Firm McGuire Sponsel Urges Qualifying Biotech Companies to Apply for New Qualifying Therapeutic Discovery Project Credit Soon

INDIANAPOLIS, June 1 /PRNewswire/ -- Small- to mid-sized biotech companies can soon apply for a new tax incentive that allows them to claim a credit for 50 percent of their qualified investment in new medical technologies for tax years 2009 and 2010.

The Qualifying Therapeutic Discovery Project Credit is part of the Patient Protection and Affordable Care Act created by the Obama administration and signed into law in March. The bill states that qualified therapeutic discovery projects must involve activities that are designed to treat areas of unmet medical need. New technologies can also be designed to prevent, detect, treat and potentially cure chronic or acute diseases and conditions.

"The incentive will provide the capital these biotech companies need to further their research and development programs in hopes of creating new treatments, therapies and cures for disease," said TJ Sponsel, director at specialty tax firm McGuire Sponsel. "It is a great opportunity for qualifying companies but they have to act fast. Once the money is gone, it's gone."

Companies applying for the credit must submit applications from June 21 through July 21. The Internal Revenue Service will issue certifications by Oct. 29. Taxpayers must file a separate application for each qualified investment being pursued and qualified investments are capped at $10 million per taxpayer.

"Qualified investments include wages, supplies and lab costs, depreciable property, contractor costs and other development costs," Sponsel said. "There will be an emphasis placed on qualitative aspects of the research and experimentation focused on creating high-quality, high-paying jobs in the U.S. and advancing the country's overall competitiveness in the fields of life, biological and medical sciences."

All claims must be substantiated with supporting narratives, including a discussion of scientific rationale and evidence relied on for the project, a description of the nature of development of the project and a description of the resources, management experience and organizational capacity of the applicant. Congress has asked the treasury department to approve qualified applications within 30 days.

To learn more in-depth details and guidelines for applying for a Qualifying Therapeutic Discovery Project Credit, visit or call Sponsel at (317) 564-5002.

SOURCE McGuire Sponsel
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
2. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
3. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
4. Diplomat Specialty Pharmacy Hires Vice President of Managed Markets
5. Diplomat Specialty Pharmacy Hires National Accounts Manager to Expand Multiple Sclerosis Program
6. Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation
7. West Pharmaceutical Services to Present at the 2008 UBS Global Specialty & Generic Pharmaceuticals Conference
8. Atrium completes the sale of its Active Ingredients and Specialty Chemicals division
9. 60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey
10. Diplomat Specialty Pharmacy Sponsors National Managed Care Roundtable for Industry Executive Advisory Board
11. A Perfect Storm Threatens Patient Access to Specialty Medical Care
Post Your Comments:
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... . The Global ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):